Background: The aim of this study was to validate the baseline characteristics of the RIETE cohort against the much larger national Spanish population-based database.
Methods: The RIETE is an ongoing registry of consecutive patients with symptomatic, objectively confirmed, acute venous thromboembolism (VTE). We compared some baseline characteristics and death rates in the administrative database from the Spanish Ministry of Health (CMBD, Conjunto Mínimo Básico de Datos) with those in the RIETE registry.
Results: During the study period, data on 87,733 patients with VTE were collected from the CMBD and 8053 from the RIETE. There were no differences between the groups in gender, mean age, clinical presentation of the VTE event, or the presence of recent surgery; however, chronic lung disease, chronic heart failure, and pregnancy were slightly more common in patients in the CMBD. There were no differences in mortality rate in patients with deep vein thrombosis, but the 12% death rate in patients with pulmonary embolism in the CMBD was three times higher than the 4.1% found in the RIETE. However, when only considering patients with pulmonary embolism who had objective tests, the 4.8% death rate in the CMBD no longer differed from the mortality in the RIETE.
Conclusions: Our data reveal that the information in the RIETE is very close to that observed in the CMBD, thus supporting the validity of the data in the RIETE.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejim.2007.06.026 | DOI Listing |
J Clin Med
January 2025
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
: The incidences of venous thromboembolism (VTE) in patients undergoing neurological surgeries vary. The objectives were to assess the incidence and risk factors of VTE, bleeding and all-cause mortality in patients undergoing neurological surgery. : This retrospective cohort study was conducted at a single center, a university-based hospital in Thailand.
View Article and Find Full Text PDF: The optimal venous thromboembolism (VTE) chemoprophylaxis approach after hip or knee total joint arthroplasty (TJA) remains controversial. This study aimed to characterize antithrombotic-related complications associated with various chemoprophylaxis regimens after TJA and to assess our current institutional risk-stratified prescribing tool. : This retrospective case-control study and regression analysis included elective unilateral TJA patients at a single institution between 1 July 2015 and 31 December 2021.
View Article and Find Full Text PDFMedicina (Kaunas)
December 2024
Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, 28031 Madrid, Spain.
: Venous thromboembolism (VTE) can be the first manifestation of an underlying cancer. This study aimed to develop a predictive model to assess the risk of occult cancer between 30 days and 24 months after a venous thrombotic event using machine learning (ML). : We designed a case-control study nested in a cohort of patients with VTE included in a prospective registry from two Spanish hospitals between 2005 and 2021.
View Article and Find Full Text PDFBiomolecules
January 2025
Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, University of Pisa, 56126 Pisa, Italy.
Cancer is characterized by chronic inflammation and hypercoagulability, with an excess of venous thromboembolism (VTE). Tissue factor, the initiator of blood coagulation, circulates associated with extracellular vesicles (EV-TF). Studies investigating EV-TF between cancer-associated and non-cancer-associated VTE are lacking.
View Article and Find Full Text PDFCancers (Basel)
January 2025
Department of Medicine I, Division of Haematology & Haemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Improved efficacy has been shown for amivantamab and amivantamab-based combination therapies in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) compared to established treatment options in clinical trials. However, a high risk of venous thromboembolism (VTE) was observed in patients treated with amivantamab-based therapies, with considerable differences in VTE risk according to the line of systemic treatment, concomitant treatment with lazertinib, and intravenous vs. subcutaneous amivantamab administration.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!